Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • Seed Grant News
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Where to Begin
    • Caregivers & Families
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Resources →
      • NCCN Guidelines for Patients
      • Patient Support Tools
      • Create Your Health Care Team
      • Patient Health Diaries
      • Support Groups
      • Financial Aid
  • HOW YOU CAN HELP
    • Planned Giving
    • Donor-Advised Funds
    • Event Calendar
    • Get Inspired
    • Fundraising Resources
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • More Ways to Give →
      • You Can Help Funds
      • Host Your Own Event
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Bomi Lee, PhD

Bomi Lee, PhD

Bomi Lee, PhD
Bomi Lee, PhD
Instructor
Department of Pediatrics, Gastroenterology
Stanford University
Palo Alto, CA

Role of the CCL20-CCR6 axis in pancreatic cancer.

Overview

Aim: Biology

Pancreatic cancer is the 4th leading cause of cancer-related mortality in the US, representing an extremely lethal disease. Current treatment options are limited to conventional cytotoxic chemotherapy, and more effective treatment options are urgently needed. Chronic inflammatory condition is a prerequisite to all cancers, including pancreatic cancer. Chronic pancreatitis (CP) increases the risk of pancreatic cancer. However, it is unclear how chronic inflammatory conditions in the tissue microenvironment initiate and promote pancreatic cancer development. Our previous multi-omics analyses study with human CP tissues identified significantly elevated expression of chemokine ligand 20 (CCL20) and chemokine receptor 6 (CCR6), suggesting a potential pathogenic role of the axis in CP. Recently, our analysis of serum samples from acute pancreatitis (AP) and CP patients using the high dimensional proteomic analysis revealed a gradual increase in the level of CCL20 over the disease continuum from AP to CP, suggesting a correlation of CCL20 in pancreatitis disease progression. In addition, our pilot analysis of The Cancer Genome Atlas (TCGA) data from PDAC subjects revealed significantly increased CCL20/CCR6 mRNA expression levels in PDAC patients compared with healthy controls and an inverse correlation between CCL20 expression and PDAC patient survival rate, demonstrating that increased expression of the CCL20/CCR6 axis may be linked to PDAC disease progression. Based on our preliminary data, we hypothesize that the CCL20/CCR6 axis promotes a pro-inflammatory microenvironment in the pancreas that cooperates with oncogenic mutations and events to drive neoplastic transformation, PDAC development. We propose to 1) characterize CCL20/CCR6-associated tissue microenvironments in human CP and PDAC and 2) determine the role of the CCL20/CCR6 axis in PDAC development in vivo. Our proposed studies will significantly advance our knowledge of how the CCL20/CCR6 axis shapes a pro-tumor, inflammatory immune microenvironment to drive PDAC and unveil a novel, therapeutic approach for PDAC by targeting CCL20/CCR6.

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Financial Information
  • Contact